분자생물학 효소, 시약, 키트 시장 규모, 점유율, 동향 분석 보고서 : 제품별(키트 및 시약, 효소), 용도별(클로닝, 시퀀싱, PCR, 에피제네틱스), 최종 용도별, 지역별, 부문별 예측(2023-2030년)

Molecular Biology Enzymes, Reagents, and Kits Market Growth & Trends

The global molecular biology enzymes, reagents, and kits market size is expected to reach USD 44.67 billion by 2030, registering a CAGR of 9.65%, according to a new report by Grand View Research, Inc The growth of the market globally can be attributed to continuous advancement in technologies in the molecular biology field, the prevalence of infectious and chronic diseases, increased usage of sequencing technologies and growing omics-based research activities.

The COVID-19 pandemic exponentially increased the demand for molecular biology enzymes, reagents, and kits, and the continuous rise in cases worldwide kept the demand on the higher side. Many market players, healthcare organizations, and academic and research institutes were actively engaged in the development of vaccines and they increased the research for repurposing the existing therapeutics for the treatment of COVID-19 infection. This continuous R&D activity is expected to boost the demand for these products in the coming years. Moreover, in an effort to detect the SARS-CoV-2 virus faster, many new products were launched by the key market players, such as RNA extraction kits. For example, in June 2020, Omega Bio-tek, Inc. announced the launch of its "Mag-Bind Viral RNA Xpress Kit" for RNA isolation in a reliable and rapid manner from the nasopharyngeal swab of patient samples.

Continuous funding and investments in the field of synthetic biology and multi-omics are expanding the field of biotechnology. As per a press release in March 2022, The Bristol Centre for Engineering Biology, BrisEngBio, is an institute that supports research and discovery in synthetic biology. It is a UKRI-funded research center that has published over 325 research papers, collaborated with 8 biotech companies, and received an additional USD 117.90 million for research. This rapidly advancing field of synthetic biology and multi-omics will result in more extensive adoption of molecular biology, enzymes, kits, and reagent products, which serve as educational tools. And this adoption rate further enhances the development of innovative methods such as drug discovery, diagnostics development, and gene therapies manufacturing, hence driving the market significantly.

The key market players are expanding their global presence through never-ceasing product launches and sustained technological developments. Acquisitions, partnerships, collaborations, and manufacturing expansions are also some of the business strategies taken up by the key players to drive revenue generation in the market. For example, in January 2022, Illumina, Inc. announced a partnership with SomaLogic to develop a product by integrating Illumina's NGS technology with SomaScan Proteomics Assay. This partnership bolsters the rapidly growing high-throughput segment of the proteomics market.

Molecular Biology Enzymes, Reagents, and Kits Market Report Highlights

• By product, the kits and reagents held the largest share in 2022. The launch of new kits and reagents in response to the pandemic is one of the key reasons fueling the growth. Moreover, the repeated use of molecular biology kits and reagents in laboratory setups contributes to the growth
• By application, sequencing accounted for the largest share in 2022 due to the introduction of single-cell sequencing and the leading presence of NGS. Use of NGS for analysis of genomics, tumor diagnostics, and biomarker discovery fuels the segment growth
• By end-use, the pharma and biotech segment held the largest share in 2022. The presence of drug development pipelines, clinical trials, and continuous R&D activities require huge usage of molecular biology enzymes, kits, and reagents, thus leading to the segment growth
• North America held the largest revenue share in 2022. This is attributed to the presence of numerous key pharmaceutical and biotechnology companies in the U.S. Furthermore, the prevalence of diseases in this region and increased use of molecular diagnostics contribute to revenue generation

Table of Contents

Chapter 1. Methodology And Scope

• 1.1. Market Segmentation And Scope
  • 1.1.1. Segment Definitions
    • 1.1.1.1. Product Segment
    • 1.1.1.2. Application Segment
    • 1.1.1.3. End-Use Segment
• 1.2. Information Procurement
  • 1.2.1. Market Formulation & Data Visualization
  • 1.2.2. Data Validation & Publishing
• 1.3. Research Assumptions
• 1.4. Research Methodology
  • 1.4.1. Purchased Database
  • 1.4.2. Gvrs Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details Of Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
    • 1.7.1.1. Approach 1: Commodity Flow Approach
• 1.8. List Of Secondary Sources
• 1.9. Global Market: Cagr Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot 1
• 2.3. Segment Snapshot 2
• 2.4. Competitive Landscape Snapshot

Chapter 3. Molecular Biology Enzymes, Reagents And Kits Market Variables And Trends

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Impact Analysis
    • 3.2.1.1. Technological Advancements In The Molecular Biology Arena
    • 3.2.1.2. Rising Incidence Of Infectious Diseases And Genetic Disorders
    • 3.2.1.3. Expanding Applications Of Sequencing Technology In Molecular Biology
    • 3.2.1.4. Increase In Omics - Based R&D Programs
  • 3.2.2. Market Restraint Impact Analysis
    • 3.2.2.1. Challenges In Maintaining Privacy Of Genetic Information
    • 3.2.2.2. Reimbursement Challenges For Molecular Diagnostics
  • 3.2.3. Market Opportunities Impact Analysis
    • 3.2.3.1. Funding And Investments In The Field Of Synthetic Biology And Epigenomics
    • 3.2.3.2. Emergence Of Single - Cell Sequencing
  • 3.2.4. Market Threat Impact Analysis
    • 3.2.4.1. Challenges Pertaining To Molecular Profiling
    • 3.2.4.2. Routine Challenges In Molecular Biology
• 3.3. Impact Of Covid-19 Pandemic
• 3.4. Industry Analysis Tools
  • 3.4.1. Porter's Analysis
  • 3.4.2. Swot Analysis; By Factor (Political & Legal, Economic And Technological)

Chapter 4. Molecular Biology Enzymes, Reagents And Kits Market: Product Estimates & Trend Analysis

• 4.1. Product Movement Analysis & Market Share, 2022 & 2030
• 4.2. Molecular Biology Enzymes, Reagents And Kits Market Estimates & Forecast, By Product (USD Million)
• 4.3. Kits & Reagents
  • 4.3.1. Global Kits & Reagents Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 4.4. Enzymes
  • 4.4.1. Global Enzymes Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Molecular Biology Enzymes, Reagents And Kits Market: Application Estimates & Trend Analysis

• 5.1. Application Movement Analysis & Market Share, 2022 & 2030
• 5.2. Molecular Biology Enzymes, Reagents And Kits Market Estimates & Forecast, By Application (USD Million)
• 5.3. Cloning
  • 5.3.1. Global Cloning Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.4. Sequencing
  • 5.4.1. Global Sequencing Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.5. Pcr
  • 5.5.1. Global Pcr Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.6. Epigenetics
  • 5.6.1. Global Epigenetics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.7. Restriction Digestion
  • 5.7.1. Global Restriction Digestion Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Global Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Molecular Biology Enzymes, Reagents And Kits Market: End-Use Estimates & Trend Analysis

• 6.1. End-Use Movement Analysis & Market Share, 2022 & 2030
• 6.2. Molecular Biology Enzymes, Reagents And Kits Market Estimates & Forecast, By End-Use (USD Million)
• 6.3. Pharma & Biotech
  • 6.3.1. Global Pharma & Biotech Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.4. Academic & Research
  • 6.4.1. Global Academic & Research Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.5. Hospital & Diagnostics
  • 6.5.1. Global Hospital & Diagnostics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Global Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Molecular Biology Enzymes, Reagents And Kits Market: Regional Estimates And Trend Analysis

• 7.1. Molecular Biology Enzymes, Reagents And Kits Market: Regional Outlook
• 7.2. North America
  • 7.2.1. North America Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.2.2. U.S.
    • 7.2.2.1. Key Country Dynamics
    • 7.2.2.2. Target Disease Prevalence
    • 7.2.2.3. Competitive Scenario
    • 7.2.2.4. Regulatory Framework
    • 7.2.2.5. Reimbursement Scenario
    • 7.2.2.6. U.S. Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.2.3. Canada
    • 7.2.3.1. Key Country Dynamics
    • 7.2.3.2. Target Disease Prevalence
    • 7.2.3.3. Competitive Scenario
    • 7.2.3.4. Regulatory Framework
    • 7.2.3.5. Reimbursement Scenario
    • 7.2.3.6. Canada Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.3. Europe
  • 7.3.1. Europe Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.2. Germany
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Target Disease Prevalence
    • 7.3.2.3. Competitive Scenario
    • 7.3.2.4. Regulatory Framework
    • 7.3.2.5. Reimbursement Scenario
    • 7.3.2.6. Germany Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.3. Uk
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Target Disease Prevalence
    • 7.3.3.3. Competitive Scenario
    • 7.3.3.4. Regulatory Framework
    • 7.3.3.5. Reimbursement Scenario
    • 7.3.3.6. Uk Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.4. France
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Target Disease Prevalence
    • 7.3.4.3. Competitive Scenario
    • 7.3.4.4. Regulatory Framework
    • 7.3.4.5. Reimbursement Scenario
    • 7.3.4.6. France Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.5. Italy
    • 7.3.5.1. Key Country Dynamics
    • 7.3.5.2. Target Disease Prevalence
    • 7.3.5.3. Competitive Scenario
    • 7.3.5.4. Regulatory Framework
    • 7.3.5.5. Reimbursement Scenario
    • 7.3.5.6. Italy Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.6. Spain
    • 7.3.6.1. Key Country Dynamics
    • 7.3.6.2. Target Disease Prevalence
    • 7.3.6.3. Competitive Scenario
    • 7.3.6.4. Regulatory Framework
    • 7.3.6.5. Reimbursement Scenario
    • 7.3.6.6. Spain Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.7. Denmark
    • 7.3.7.1. Key Country Dynamics
    • 7.3.7.2. Target Disease Prevalence
    • 7.3.7.3. Competitive Scenario
    • 7.3.7.4. Regulatory Framework
    • 7.3.7.5. Reimbursement Scenario
    • 7.3.7.6. Denmark Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.8. Sweden
    • 7.3.8.1. Key Country Dynamics
    • 7.3.8.2. Target Disease Prevalence
    • 7.3.8.3. Competitive Scenario
    • 7.3.8.4. Regulatory Framework
    • 7.3.8.5. Reimbursement Scenario
    • 7.3.8.6. Sweden Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.3.9. Norway
    • 7.3.9.1. Key Country Dynamics
    • 7.3.9.2. Target Disease Prevalence
    • 7.3.9.3. Competitive Scenario
    • 7.3.9.4. Regulatory Framework
    • 7.3.9.5. Reimbursement Scenario
    • 7.3.9.6. Norway Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.4. Asia Pacific
  • 7.4.1. Asia Pacific Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. Japan
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Competitive Scenario
    • 7.4.2.4. Regulatory Framework
    • 7.4.2.5. Reimbursement Scenario
    • 7.4.2.6. Japan Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. China
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Competitive Scenario
    • 7.4.3.4. Regulatory Framework
    • 7.4.3.5. Reimbursement Scenario
    • 7.4.3.6. China Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. India
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Competitive Scenario
    • 7.4.4.4. Regulatory Framework
    • 7.4.4.5. Reimbursement Scenario
    • 7.4.4.6. India Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.5. South Korea
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Target Disease Prevalence
    • 7.4.5.3. Competitive Scenario
    • 7.4.5.4. Regulatory Framework
    • 7.4.5.5. Reimbursement Scenario
    • 7.4.5.6. South Korea Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.6. Australia
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Target Disease Prevalence
    • 7.4.6.3. Competitive Scenario
    • 7.4.6.4. Regulatory Framework
    • 7.4.6.5. Reimbursement Scenario
    • 7.4.6.6. Australia Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.7. Thailand
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Target Disease Prevalence
    • 7.4.7.3. Competitive Scenario
    • 7.4.7.4. Regulatory Framework
    • 7.4.7.5. Reimbursement Scenario
    • 7.4.7.6. Thailand Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.5. Latin America
  • 7.5.1. Latin America Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. Brazil
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Competitive Scenario
    • 7.5.2.4. Regulatory Framework
    • 7.5.2.5. Reimbursement Scenario
    • 7.5.2.6. Brazil Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Competitive Scenario
    • 7.5.3.4. Regulatory Framework
    • 7.5.3.5. Reimbursement Scenario
    • 7.5.3.6. Mexico Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. Argentina
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Competitive Scenario
    • 7.5.4.4. Regulatory Framework
    • 7.5.4.5. Reimbursement Scenario
    • 7.5.4.6. Argentina Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.6. MEA
  • 7.6.1. MEA Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. South Africa
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Competitive Scenario
    • 7.6.2.4. Regulatory Framework
    • 7.6.2.5. Reimbursement Scenario
    • 7.6.2.6. South Africa Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. Saudi Arabia
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Competitive Scenario
    • 7.6.3.4. Regulatory Framework
    • 7.6.3.5. Reimbursement Scenario
    • 7.6.3.6. Saudi Arabia Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. UAE
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Competitive Scenario
    • 7.6.4.4. Regulatory Framework
    • 7.6.4.5. Reimbursement Scenario
    • 7.6.4.6. UAE Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Kuwait
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Competitive Scenario
    • 7.6.5.4. Regulatory Framework
    • 7.6.5.5. Reimbursement Scenario
    • 7.6.5.6. Kuwait Molecular Biology Enzymes, Reagents And Kits Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Molecular Biology Enzymes, Reagents And Kits Market: Competitive Landscape

• 8.1. Participant Categorization
  • 8.1.1. Thermo Fisher Scientific, Inc.
    • 8.1.1.1. Overview
    • 8.1.1.2. Product Benchmarking
    • 8.1.1.3. Strategic Initiatives
  • 8.1.2. Illumina, Inc.
    • 8.1.2.1. Overview
    • 8.1.2.2. Product Benchmarking
    • 8.1.2.3. Strategic Initiatives
  • 8.1.3. Agilent Technologies, Inc.
    • 8.1.3.1. Overview
    • 8.1.3.2. Financial Performance (Net Revenue/Sales/Ebitda/Gross Profit)
    • 8.1.3.3. Product Benchmarking
    • 8.1.3.4. Strategic Initiatives
  • 8.1.4. Qiagen
    • 8.1.4.1. Overview
    • 8.1.4.2. Financial Performance (Net Revenue/Sales/Ebitda/Gross Profit)
    • 8.1.4.3. Product Benchmarking
    • 8.1.4.4. Strategic Initiatives
  • 8.1.5. Promega Corporation
    • 8.1.5.1. Overview
    • 8.1.5.2. Financial Performance (Net Revenue/Sales/Ebitda/Gross Profit)
    • 8.1.5.3. Product Benchmarking
    • 8.1.5.4. Strategic Initiatives
  • 8.1.6. New England Biolabs
    • 8.1.6.1. Overview
    • 8.1.6.2. Financial Performance (Net Revenue/Sales/Ebitda/Gross Profit)
    • 8.1.6.3. Product Benchmarking
    • 8.1.6.4. Strategic Initiatives
  • 8.1.7. Merck Kgaa
    • 8.1.7.1. Overview
    • 8.1.7.2. Financial Performance (Net Revenue/Sales/Ebitda/Gross Profit)
    • 8.1.7.3. Product Benchmarking
    • 8.1.7.4. Strategic Initiatives
  • 8.1.8. F. Hoffmann-La Roche Ltd.
    • 8.1.8.1. Overview
    • 8.1.8.2. Financial Performance (Net Revenue/Sales/Ebitda/Gross Profit)
    • 8.1.8.3. Product Benchmarking
    • 8.1.8.4. Strategic Initiatives
  • 8.1.9. Bio-Rad Laboratories, Inc.
    • 8.1.9.1. Overview
    • 8.1.9.2. Financial Performance (Net Revenue/Sales/Ebitda/Gross Profit)
    • 8.1.9.3. Product Benchmarking
    • 8.1.9.4. Strategic Initiatives
  • 8.1.10. Takara Bio, Inc.
    • 8.1.10.1. Overview
    • 8.1.10.2. Financial Performance (Net Revenue/Sales/Ebitda/Gross Profit)
    • 8.1.10.3. Product Benchmarking
    • 8.1.10.4. Strategic Initiatives
  • 8.1.11. Lgc Limited
    • 8.1.11.1. Overview
    • 8.1.11.2. Financial Performance (Net Revenue/Sales/Ebitda/Gross Profit)
    • 8.1.11.3. Product Benchmarking
    • 8.1.11.4. Strategic Initiatives
• 8.2. Participant's Overview
• 8.3. Financial Performance
• 8.4. Product Benchmarking
• 8.5. Company Market Share Analysis, 2022
• 8.6. Strategy Mapping
  • 8.6.1. Expansion
  • 8.6.2. Acquisition
  • 8.6.3. Product/Service Launch
  • 8.6.4. Others

Chapter 9. Analyst View